Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

864.08 -1.75 (-0.20%)
Streaming Delayed Price Updated: 11:07 AM EDT, Jun 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
82 83 Next >
Jim Cramer Weighs In On Palo Alto, Eli Lilly And Salesforce, Says Price Target Bump For This Stock A 'Red Flag'
During Tuesday's CNBC Investing Club Morning Meeting, U.S. stocks exhibited mixed performance, prompting a closer look at prevailing market themes. Cybersecurity emerged as a key focus, with Jim Cramer... 
Via Benzinga
Why Novo Nordisk and Eli Lilly Stocks Slipped Today
A competitor to Wegovy and Zepbound might appear on pharmacy shelves before long. 
Via The Motley Fool
Are Nvidia, Eli Lilly, AMD's High Equity Valuations In Peril From Higher Rates?
The Fed's aggressive rate cycle in 2022 and 2023 did not fundamentally spook equities anywhere near as much as what happened in the 1970s. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
Stock Spotlight: 3 Picks ChatGPT Urges You Not to Miss
Everybody seems to want ChatGPT stock picks now that generative AI is popular with investors. Here are three recommended by the app. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Harvard Business Professor on Failing Well
Why would Eli Lilly put on a failure party? 
Via The Motley Fool
Assessing Eli Lilly and Co's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
What the Options Market Tells Us About Eli Lilly and Co
Via Benzinga
Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect
Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks. 
Via Benzinga
Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results
Eli Lilly and Novo Nordisk fell modestly. 
Via Investor's Business Daily
Warren Buffett's Berkshire Hathaway, Elon Musk's Tesla And Eli Lilly Could Be Next Trillion-Dollar Companies After Nvidia's Rapid Ascension: Jim Cramer
CNBC's Jim Cramer has identified three companies that could potentially join the trillion-dollar club, in the wake of Nvidia rapid ascension. 
Via Benzinga
Future Juggernauts: The Next 7 Trillion Dollar Companies to Buy Now
The seven companies discussed here have every chance of becoming the next trillion dollar stocks for investors. 
Via InvestorPlace
Could Eli Lilly Stock Help You Become a Millionaire?
Shares of Eli Lilly have risen by roughly 1,190% over the past 10 years. 
Via The Motley Fool
Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs
Amgen's growth outlook in 2024, with updates on key programs and upcoming catalysts. Goldman Sachs sees significant opportunities despite exclusivity losses. Dive into potential market moves and... 
Via Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024. 
Via InvestorPlace
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
This Warren Buffett Stock Is On The Cusp Of Joining The $1 Trillion Club
Berkshire Hathaway is just below a $1 trillion market cap. 
Via Investor's Business Daily
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings. 
Via InvestorPlace
DexCom: A Winner In Diabetes Management
Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820... 
Via Talk Markets
Is Eli Lilly Stock Going to $950? 1 Wall Street Analyst Thinks So.
The price tag may seem high already, but it might be just the start. 
Via The Motley Fool
3 Dividend Stocks That Are No-Brainer Buys Right Now
These stocks check off multiple boxes for investors. 
Via The Motley Fool
Obesity Solutions Like Weight Loss Drugs To Act As Catalyst For Economic Surge, Goldman Sachs Forecasts
Goldman Sachs predicts a potential 1% GDP boost from GLP-1 agonists market. Novo Nordisk and Eli Lilly lead, with analysts foreseeing 10-70 million users by 2028. AI-powered drug discovery and... 
Via Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
Here's 1 Pharmaceutical Stock That Looks Unstoppable. Hint: It's Not Novo Nordisk.
Eli Lilly is home to many blockbuster drugs including Mounjaro, Jardiance, Zepbound, and more. 
Via The Motley Fool
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Why Eli Lilly Stock Was Feeling Sickly on Wednesday
The company's surging popularity has made it expensive in terms of valuation. 
Via The Motley Fool
Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for February 2024
Here are just a few of the top growth stocks investors may want to seriously consider as we get deeper into the new year. 
Via InvestorPlace
3 Stocks With the Potential to Knock Tesla Out of the Magnificent 7
These stocks are best positioned to usurp Tesla's position within Magnificent 7 stocks as it slumps further in February. 
Via InvestorPlace
Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7
Goldman Sachs' Hedge Fund Trend Monitor highlights concentration in mega-caps, with optimism in AI and health care. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
82 83 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.